Tamtam Try Tamtam free
McKesson logo

McKesson account plan

Healthcare solutions and services

At a glance

McKesson is a U.S. healthcare services group built on drug distribution in North America: $403,430 million FY2026 revenue, 43,000+ employees.

McKesson, based in Irving, Texas, works with biopharma companies, care providers, pharmacies, manufacturers and governments; its core is wholesale drug distribution in the U.S. and Canada, surrounded by specialty and oncology provider services, prescription-access technology and medical-surgical supply. It says it distributes about 1/3 of pharmaceuticals in North America. In the fiscal year to March 31, 2026 (FY2026) revenues were $403,430 million (+12%), net income attributable to McKesson $4,762 million (+45%) and diluted EPS $38.38. It had more than 43,000 employees at March 31, 2026, about 38,000 of them in the U.S. and 5,000 in Canada. Brian S. Tyler has been CEO since April 2019 and Chairman since May 1, 2026.

Business units

Strategic priorities

Grow oncology and multispecialty
Expand the community specialty platform through physician recruitment, geographic expansion and tuck-in acquisitions; FY2027 guidance is O&M operating profit +13.5% to 17.5%, and the long-term target is +13% to 16%.
Separate Medical-Surgical as Wellverse
The business is "now operationally and legally separate" with its own capital structure (a $2.25 billion Term Loan B set up on June 9, 2026); an IPO is planned, with proceeds going principally to share repurchases.
Expand biopharma access services
Prescription Technology Solutions supported a record 3.4 million patients in the annual verification season and launched an integrated specialty access and affordability solution; it began supporting the CMS Medicare GLP-1 Bridge program in July 2026.
Cost and operating-model programmes
Three restructuring programmes run in parallel: enterprise technology operating-model initiatives ($650-700M, through FY2028), an RxTS efficiency programme ($200-250M, through FY2029) and new Corporate initiatives ($230-310M, through FY2028).
Invest in AI and distribution automation
The NAP outlook includes accelerated second-half FY2027 investments focused on growth and AI, with returns most likely from the beginning of 2028; a new Montreal distribution center uses AI and robots.
Capital return
About $5 billion of buybacks planned in FY2027 and free cash flow of about $4.5-4.9 billion; the quarterly dividend was raised to $0.94 from $0.82 in July 2026.

Latest results

In Q1 FY2027 (quarter to June 30, 2026) revenues rose 8% to $105,380M and adjusted EPS rose 20% to $9.93. GAAP diluted EPS fell to $5.15 from $6.25 because of a $293M charge to remeasure the Apollo minority interest in Medical-Surgical Solutions. Oncology & Multispecialty revenue grew 33% and adjusted segment operating profit 41%, while Medical-Surgical adjusted operating profit fell 20% on product mix and one-time administrative expenses. GLP-1 distribution revenue was $15 billion in the quarter (+24%). FY2027 adjusted EPS guidance was raised to $44.20-$45.00 (13% to 15% growth), with revenue growth of 5% to 9%.

Investments and deals

Option Care Health stake
On October 6, 2026 CD&R and McKesson agreed to acquire Option Care Health, the largest independent U.S. home and alternate-site infusion provider, at an enterprise value of about $5.8 billion; McKesson invests about $1.4 billion for about 49%, with closing expected in the first half of calendar 2027.
Oncology and retina acquisitions
Acquired 80% of PRISM Vision for $875M (April 1, 2025) and 70% of Core Ventures, the Florida Cancer Specialists services organisation, for $2.5B (June 2, 2025).
Distribution centers
Broke ground on a regional distribution center in Moore, Oklahoma that will raise throughput by 75%, after opening an AI- and robot-equipped Montreal distribution center.
Exit from Europe
Sold the Norwegian business on January 30, 2026 for $821M, completing the European exit.
Capital spending
FY2026 capex was $436M of property, plant and equipment plus $309M of capitalised software; Q1 FY2027 capex was $152M.

Challenges and risks

Opioid litigation
Many cases by states, counties and municipalities, with an estimated accrued liability of $5.7B at March 31, 2026.
Drug-pricing policy
IRA price negotiation (Part D changes from January 2028), the most-favored-nation executive order, the CMS bona fide service fee rule and 340B reform, on which Tyler says it is premature to estimate the impact.
Customer concentration
The ten largest customers were about 73% of FY2026 revenues, CVS Health alone about 24%, with the distribution partnership extended to June 2027.
Thin distribution margins
Gross profit margin was 3.61% in FY2026, and branded price decreases and brand-to-generic conversion weigh on distribution revenue.
Separation and cyber risk
The 10-K names execution and tax risk on the Med-Surg separation, cybersecurity incidents and AI adoption risks among its main risks.

What leadership says

“Our first quarter performance exceeded our expectations, highlighted by 20% growth in Adjusted Earnings per Diluted Share.”

Brian S. Tyler, Chair and Chief Executive Officer · Q1 fiscal 2027 earnings release, August 5, 2026

“The raise in full year Adjusted Earnings per Diluted Share outlook reflects strong first quarter performance and sustainable operational momentum.”

Kenny Cheung, Chief Financial Officer · Q1 fiscal 2027 earnings release, August 5, 2026

“This investment represents an important opportunity that aligns with McKesson's long-term strategy to expand access and affordability to innovative therapies across the care continuum.”

Brian S. Tyler, Chair and Chief Executive Officer · Option Care Health acquisition press release, October 6, 2026

“another great year of execution and disciplined portfolio actions”

Brian S. Tyler, Chief Executive Officer · FQ4 2026 earnings call, May 7, 2026

Where a supplier can help

Wellverse standalone set-up
The Medical-Surgical separation into Wellverse, operating under that name from January 2027 with a planned IPO, creates needs for standalone systems, finance and branding.
AI and automation tooling
Accelerated second-half FY2027 investment in growth and AI, plus the Corporate initiatives on process enhancements and automation, open room for AI, data and workflow-automation suppliers.
Distribution center build-out
The new Moore, Oklahoma distribution center and the AI- and robot-equipped Montreal site point to demand for warehouse automation, robotics and logistics software.
Oncology practice growth
Growth in Oncology & Multispecialty through physician recruitment, geographic expansion and tuck-ins favours suppliers of practice software, recruiting and clinical data services.
Cost-programme efficiency
Three restructuring programmes totalling well over $1 billion of charges create openings for outsourcing, process and technology vendors that can show measurable savings.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like McKesson?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about McKesson

What does McKesson do?

McKesson is a healthcare services company whose core is wholesale drug distribution in the U.S. and Canada. It also runs oncology and multispecialty provider services, prescription-access technology for biopharma and a medical-surgical supply business being separated as Wellverse.

What is McKesson's revenue?

Revenues were $403,430 million in the fiscal year to March 31, 2026, up 12%. In Q1 FY2027 (to June 30, 2026) revenues were $105,380M, up 8%.

How many employees does McKesson have?

More than 43,000 at March 31, 2026: about 38,000 in the U.S. and 5,000 in Canada.

Who leads McKesson?

Brian S. Tyler is Chair and CEO (CEO since April 2019). Kenny Cheung joined as CFO in May 2026, and Ramesh Srinivasan became Chief Strategy Officer on August 1, 2026.

What is McKesson's strategy?

Grow oncology and multispecialty and biopharma access services, separate Medical-Surgical as Wellverse, invest in AI and distribution automation, and return cash through buybacks and dividends.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)